A Study Of Auricular Transcutaneous Vagus Nerve Stimulation In Chronic Dizziness

Overview

About this study

The purpose of this study is to measure the change in dizziness, as measured by change in Dizziness Handicap Inventory (DHI) score, following a 4-week treatment period with aurical transcutaneous vagus nerve stimulation (aTVNS).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18–75, PPPD diagnosis per ICVD.

  • Persistent dizziness ≥3 months and at least 1 dizziness exacerbation/day during 2-week run-in.

  • On stable medications/therapy for ≥4 weeks prior to baseline (if any).

 

Exclusion Criteria: 

  • Uncompensated peripheral/central vestibular deficit, sensory-afferent or cerebellar ataxia.

  • Cardiac disease (coronary disease, unstable arrhythmia), recurrent syncope (>1 in past 12 months).

  • Neck surgery, vagotomy, or any condition interfering with vagal stimulation.

  • Pregnancy.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 01/05/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Colton Clayton, Au.D., Ph.D.

Contact us for the latest status

Contact information:

Colton Clayton

9049536788

clayton.colton@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20598503

Mayo Clinic Footer